Literature DB >> 26575206

The extent of whole-genome copy number alterations predicts aggressive features in primary melanomas.

Greta Gandolfi1, Caterina Longo2, Elvira Moscarella2, Iris Zalaudek3, Valentina Sancisi1, Margherita Raucci2, Gloria Manzotti1, Mila Gugnoni1, Simonetta Piana4, Giuseppe Argenziano2,5, Alessia Ciarrocchi1.   

Abstract

Recent evidence indicates that melanoma comprises distinct types of tumors and suggests that specific morphological features may help predict its clinical behavior. Using a SNP-array approach, we quantified chromosomal copy number alterations (CNA) across the whole genome in 41 primary melanomas and found a high degree of heterogeneity in their genomic asset. Association analysis correlating the number and relative length of CNA with clinical, morphological, and dermoscopic attributes of melanoma revealed that features of aggressiveness were strongly linked to the overall amount of genomic damage. Furthermore, we observed that melanoma progression and survival were mainly affected by a low number of large chromosome losses and a high number of small gains. We identified the alterations most frequently associated with aggressive melanoma, and by integrating our data with publicly available gene expression profiles, we identified five genes which expression was found to be necessary for melanoma cells proliferation. In conclusion, this work provides new evidence that the phenotypic heterogeneity of melanoma reflects a parallel genetic diversity and lays the basis to define novel strategies for a more precise prognostic stratification of patients.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  aggressiveness; copy number alterations; dermoscopy; primary melanoma; whole-genome SNP array

Mesh:

Year:  2016        PMID: 26575206     DOI: 10.1111/pcmr.12436

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  7 in total

Review 1.  Dermoscopic Features as Predictors of BRAF Mutational Status and Sentinel Lymph Node Positivity in Primary Cutaneous Melanoma.

Authors:  Nika Filipović; Mirna Šitum; Marija Buljan
Journal:  Dermatol Pract Concept       Date:  2021-04-12

2.  Stratification of clear cell renal cell carcinoma (ccRCC) genomes by gene-directed copy number alteration (CNA) analysis.

Authors:  H-J Thiesen; F Steinbeck; M Maruschke; D Koczan; B Ziems; O W Hakenberg
Journal:  PLoS One       Date:  2017-05-09       Impact factor: 3.240

3.  Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma.

Authors:  Tiziana Petrachi; Alessandra Romagnani; Adriana Albini; Caterina Longo; Giuseppe Argenziano; Giulia Grisendi; Massimo Dominici; Alessia Ciarrocchi; Katiuscia Dallaglio
Journal:  Oncotarget       Date:  2017-01-24

4.  Organ Specific Copy Number Variations in Visceral Metastases of Human Melanoma.

Authors:  Orsolya Papp; Viktória Doma; Jeovanis Gil; György Markó-Varga; Sarolta Kárpáti; József Tímár; Laura Vízkeleti
Journal:  Cancers (Basel)       Date:  2021-11-28       Impact factor: 6.639

5.  Modeling the dynamics of chromosomal alteration progression in cervical cancer: A computational model.

Authors:  Augusto Cabrera-Becerril; Cruz Vargas-De-León; Sergio Hernández; Pedro Miramontes; Raúl Peralta
Journal:  PLoS One       Date:  2017-07-19       Impact factor: 3.240

Review 6.  Intratumor and Intertumor Heterogeneity in Melanoma.

Authors:  Tomasz M Grzywa; Wiktor Paskal; Paweł K Włodarski
Journal:  Transl Oncol       Date:  2017-10-24       Impact factor: 4.243

7.  Genome-wide profiling identifies the THYT1 signature as a distinctive feature of widely metastatic Papillary Thyroid Carcinomas.

Authors:  Greta Gandolfi; Moira Ragazzi; Dario de Biase; Michela Visani; Eleonora Zanetti; Federica Torricelli; Valentina Sancisi; Mila Gugnoni; Gloria Manzotti; Luca Braglia; Silvio Cavuto; Domenico Franco Merlo; Giovanni Tallini; Andrea Frasoldati; Simonetta Piana; Alessia Ciarrocchi
Journal:  Oncotarget       Date:  2017-12-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.